Table 1: Characteristics of studies included in the meta-analysis.

Study Title, Author, and Year of Publication

Population and Study Design

Intervention

 

Outcomes Measured

Follow-up Duration

 

Evaluation of Bromocriptine in the treatment of acute severe peripartum cardiomyopathy

 

Sliwa, et al. [16]

 

 

Total N = 20 patients

 

Mean Age: 26 8

 

 

NYHA fc II: 50%

NYHA fc III/IV: 50%

 

 

Baseline LVEF (%): 27 7.9

 

 

Randomized Controlled Trial

 

 

Group A (10 patients)

Standard HF Therapy:

Carvedilol 6.25 mg - 12.5 mg BID;

Enalapril 5 mg - 10 mg OD;

Furosemide 80 mg - 120 mg OD

 

 

Group B (10 patients)

Bromocriptine 2.5 mg BID 2 weeks then OD 6 weeks on top of Standard HF therapy

 

 

        Cardiovascular Mortality

 

        Left Ventricular Ejection Fraction

 

        Worsening NYHA functional class III / IV

 

        6 months

 

 

Bromocriptine in management of peripartum cardiomyopathy: A randomized study on 96 women in Burkina Faso.

 

 

Yameogo, et al. [17]

 

 

 

 

Total N = 96 patients

 

Mean Age: 29.4 3.4

 

 

NYHA fc III: 28.12%

NYHA fc IV: 71.88%

 

 

Baseline LVEF (%): 36.4 5.5

 

Randomized Controlled Trial

 

 

Group A (48 patients):

Standard HF therapy:

Captopril 6.25 mg - 25 mg OD

Furosemide 80 mg OD

 

 

Group B (48 patients):

Bromocriptine 2.5 mg BID 4 weeks on top of standard HF therapy

 

 

        Cardiovascular Mortality

 

        Echocardiographic parameters:

 

LVEDD, LVESD, TAPSE and LVEF

 

        Change in dyspnea

 

        2 weeks

 

        1 month

 

        3 months

 

        6 months

 

        12 months

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HF: Heart Failure; LVEF: Left Ventricular Ejection Fraction; NYHA: New York Heart Functional Class; LVEDD: Left Ventricular End Diastolic Diameter;

LVESD: Left Ventricular End Diastolic Diameter; TAPSE: Tricuspid Annular Plane Systolic Excursion.